Nazira J. Albargothy

Nazira J. Albargothy

Auto-generated profile, based on publicly available information

Nazira J. Albargothy

University of Southampton, Hampshire, United Kingdom

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2016 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
AMAlan W. J. Morris
Alan W. J. Morris
MSMatthew MacGregor Sharp
Matthew MacGregor Sharp
NANazira J. Albargothy
Nazira J. Albargothy
RFRute Fernandes
Rute Fernandes
CHCheryl Hawkes
Cheryl Hawkes
RCRoxana Octavia Carare
Roxana Octavia Carare
In the absence of conventional lymphatics, drainage of interstitial fluid and solutes from the brain parenchyma to cervical lymph nodes is along basement membranes in the walls of cerebral capillaries and tunica media of arteries. Perivascular pathways are also involved in the entry of CSF into the brain by the convective influx/glymphatic system. The objective of this study is to differentiate the cerebral vascular basement membrane pathways by which fluid passes out of the brain from the pathway by which CSF enters the brain. Experiment 1: 0.5 µl of soluble biotinylated or fluorescent Aβ, or 1 µl 15 nm gold nanoparticles was injected into the mouse hippocampus and their distributions determined at 5 min by transmission electron microscopy. Aβ was distributed within the extracellular spaces of the hippocampus and within basement membranes of capillaries and tunica media of arteries. Nanoparticles did not enter capillary basement membranes from the extracellular spaces. Experiment 2: 2 µl of 15 nm nanoparticles were injected into mouse CSF. Within 5min, groups of nanoparticles were present in the pial-glial basement membrane on the outer aspect of cortical arteries between the investing layer of pia mater and the glia limitans. The results of this study and previous research suggest that cerebral vascular basement membranes form the pathways by which fluid passes into and out of the brain but that different basement membrane layers are involved. The significance of these findings for neuroimmunology, Alzheimer’s disease, drug delivery to the brain and the concept of the Virchow–Robin space are discussed.

12 May 2018 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
NANazira J. Albargothy
Nazira J. Albargothy
DJDavid Annandale Johnston
David Annandale Johnston
MSMatthew MacGregor Sharp
Matthew MacGregor Sharp
RWRoy O. Weller
Roy O. Weller
AVAjay Verma
Ajay Verma
RCRoxana Octavia Carare
Roxana Octavia Carare
Tracers injected into CSF pass into the brain alongside arteries and out again. This has been recently termed the “glymphatic system” that proposes tracers enter the brain along periarterial “spaces” and leave the brain along the walls of veins. The object of the present study is to test the hypothesis that: (1) tracers from the CSF enter the cerebral cortex along pial-glial basement membranes as there are no perivascular “spaces” around cortical arteries, (2) tracers leave the brain along smooth muscle cell basement membranes that form the Intramural Peri-Arterial Drainage (IPAD) pathways for the elimination of interstitial fluid and solutes from the brain. 2 μL of 100 μM soluble, fluorescent fixable amyloid β (Aβ) were injected into the CSF of the cisterna magna of 6–10 and 24–30 month-old male mice and their brains were examined 5 and 30 min later. At 5 min, immunocytochemistry and confocal microscopy revealed Aβ on the outer aspects of cortical arteries colocalized with α-2 laminin in the pial-glial basement membranes. At 30 min, Aβ was colocalised with collagen IV in smooth muscle cell basement membranes in the walls of cortical arteries corresponding to the IPAD pathways. No evidence for drainage along the walls of veins was found. Measurements of the depth of penetration of tracer were taken from 11 regions of the brain. Maximum depths of penetration of tracer into the brain were achieved in the pons and caudoputamen. Conclusions drawn from the present study are that tracers injected into the CSF enter and leave the brain along separate periarterial basement membrane pathways. The exit route is along IPAD pathways in which Aβ accumulates in cerebral amyloid angiopathy (CAA) in Alzheimer’s disease. Results from this study suggest that CSF may be a suitable route for delivery of therapies for neurological diseases, including CAA.

17 October 2019 in JCI Insight
Verified
Journal Article
Closed access
CMCurt Mazur
Curt Mazur
BPBerit Powers
Berit Powers
KZKenneth Zasadny
Kenneth Zasadny
JSJenna M. Sullivan
Jenna M. Sullivan
HDHemi Dimant
Hemi Dimant
AVAjay Verma
Ajay Verma
Intrathecal (IT) delivery and pharmacology of antisense oligonucleotides (ASOs) for the CNS have been successfully developed to treat spinal muscular atrophy. However, ASO pharmacokinetic (PK) and pharmacodynamic (PD) properties remain poorly understood in the IT compartment. We applied multimodal imaging techniques to elucidate the IT PK and PD of unlabeled, radioactively labeled, or fluorescently labeled ASOs targeting ubiquitously expressed or neuron-specific RNAs. Following lumbar IT bolus injection in rats, all ASOs spread rostrally along the neuraxis, adhered to meninges, and were partially cleared to peripheral lymph nodes and kidneys. Rapid association with the pia and arterial walls preceded passage of ASOs across the glia limitans, along arterial intramural basement membranes, and along white-matter axonal bundles. Several neuronal and glial cell types accumulated ASOs over time, with evidence of probable glial accumulation preceding neuronal uptake. IT doses of anti- GluR1 and anti- Gabra1 ASOs markedly reduced the mRNA and protein levels of their respective neurotransmitter receptor protein targets by 2 weeks and anti- Gabra1 ASOs also reduced binding of the GABA A receptor PET ligand 18 F-flumazenil in the brain over 4 weeks. Our multimodal imaging approaches elucidate multiple transport routes underlying the CNS distribution, clearance, and efficacy of IT-dosed ASOs.

7 January 2017
Verified
Book Chapter
Closed access
PDF file
NANazira J. Albargothy
Nazira J. Albargothy
MSMatthew MacGregor Sharp
Matthew MacGregor Sharp
MGMaureen Gatherer
Maureen Gatherer
AMAlan Morris
Alan Morris
RWRoy O. Weller
Roy O. Weller
RCRoxana Octavia Carare
Roxana Octavia Carare